We wrote a review on GIP and GIP receptor modifying drugs!
Thanks so much to @alpanashuklamd for her mentorship and to Afua Takyi our coauthor!
https://t.co/5pWBK70g31
So thrilled to have matched at Montefiore for GI/hepatology fellowship. So grateful to my mentors, who have supported me, and looking forward to returning to the Bronx!
1/2
Study reveals #Retatrutide (triple GLP-1, GIP & glucagon agonist) significantly reduces liver fat in #MASLD patients
💉With 8 and 12 mg doses, over 80% of participants saw mean liver fat reductions
📉 hepatic steatosis resolved in over 85%!
#TLM23#LIvertwitter
Great discussion around MASH and metabolic surgery to improve outcomes from @Ali_Aminian_MD and appreciate the brief discussion around alcohol-associated liver disease after bariatric surgery #obesityweek2023
@eemoin@edyong209 His writing and the pandemic more generally have made me more rigorously consider the ethical and practical ramifications of my actions!